- 1.Smith AF, Waycaster C. Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States. BMC Ophthalmol. 2009; 9:13.
10.1186/1471-2415-9-13 Crossref Medline, Google Scholar - 2.Dart JK. Eye disease at a community health centre. Br Med J (Clin Res Ed). 1986; 293(6560):1477–1480.
10.1136/bmj.293.6560.1477 Crossref Medline, Google Scholar - 3.McDonnell PJ. How do general practitioners manage eye disease in the community?Br J Ophthalmol. 1988; 72(10):733–736.
10.1136/bjo.72.10.733 Crossref Medline, Google Scholar - 4.Høvding G. Acute bacterial conjunctivitis. Acta Ophthalmol. 2008; 86(1):5–17.
10.1111/j.1600-0420.2007.01006.x Crossref Medline, Google Scholar - 5.Galor A, Jeng BH. Red eye for the internist: when to treat, when to refer. Cleve Clin J Med. 2008; 75(2):137–144.
10.3949/ccjm.75.2.137 Crossref Medline, Google Scholar - 6.Tarabishy AB, Jeng BH. Bacterial conjunctivitis: a review for internists. Cleve Clin J Med. 2008; 75(7):507–512.
10.3949/ccjm.75.7.507 Crossref Medline, Google Scholar - 7.Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005; 115(1):118–122.
10.1016/j.jaci.2004.10.042 Crossref Medline, Google Scholar - 8.Rose PW, Harnden A, Brueggemann AB, Chloramphenicol treatment for acute infective conjunctivitis in children in primary care: a randomised double-blind placebo-controlled trial. Lancet. 2005; 366(9479):37–43.
10.1016/S0140-6736(05)66709-8 Crossref Medline, Google Scholar - 9.Gigliotti F, Williams WT, Hayden FG, Etiology of acute conjunctivitis in children. J Pediatr. 1981; 98(4):531–536.
10.1016/S0022-3476(81)80754-8 Crossref Medline, Google Scholar - 10.Teoh DL, Reynolds S. Diagnosis and management of pediatric conjunctivitis. Pediatr Emerg Care. 2003; 19(1):48–55.
10.1097/00006565-200302000-00014 Crossref Medline, Google Scholar - 11.Rose PW. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin Pharmacother. 2007; 8(12):1903–1921.
10.1517/14656566.8.12.1903 Crossref Medline, Google Scholar - 12.Patel PB, Diaz MC, Bennett JE, Attia MW. Clinical features of bacterial conjunctivitis in children. Acad Emerg Med. 2007; 14(1):1–5.
10.1111/j.1553-2712.2007.tb00359.x Crossref Medline, Google Scholar - 13.Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician. 1998; 57(4):735–746. Medline, Google Scholar
- 14.Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2006;Apr 19(2): CD001211. Google Scholar
- 15.Block SL, Hedrick J, Tyler R, Increasing bacterial resistance in pediatric acute conjunctivitis (1997–1998). Antimicrob Agents Chemother. 2000; 44(6):1650–1654.
10.1128/AAC.44.6.1650-1654.2000 Crossref Medline, Google Scholar - 16.Buznach N, Dagan R, Greenberg D. Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J. 2005; 24(9):823–828.
10.1097/01.inf.0000178066.24569.98 Crossref Medline, Google Scholar - 17.American Academy of Pediatrics. School health. In: , eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:148–150. Google Scholar
- 18.Weiss A, Brinser JH, Nazar-Stewart V. Acute conjunctivitis in childhood. J Pediatr. 1993; 122(1):10–14.
10.1016/S0022-3476(05)83479-1 Crossref Medline, Google Scholar - 19.Everitt HA, Little PS, Smith PW. A randomised controlled trial of management strategies for acute infective conjunctivitis in general practice. BMJ. 2006; 333(7563):321.
10.1136/bmj.38891.551088.7C Crossref Medline, Google Scholar - 20.Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. Paediatr Drugs. 2010; 12(2):105–112.
10.2165/11534380-000000000-00000 Crossref Medline, Google Scholar - 21.Schaller UC, Klauss V. Is Credé’s prophylaxis for ophthalmia neonatorum still valid?Bull World Health Organ. 2001; 79(3):262–263. Medline, Google Scholar
- 22.Jain S. Perinatally acquired Chlamydia trachomatis associated morbidity in young infants. J Matern Fetal Med. 1999; 8(3):130–133.
10.1002/(SICI)1520-6661(199905/06)8:3<130::AID-MFM11>3.0.CO;2-X Crossref Medline, Google Scholar - 23.Zegans ME, Sanchez PA, Likosky DS, Clinical features, outcomes, and costs of a conjunctivitis outbreak caused by the ST448 strain of Streptococcus pneumoniae. Cornea. 2009; 28(5):503–509.
10.1097/ICO.0b013e3181909362 Crossref Medline, Google Scholar - 24.Van Dort M, Walden C, Walker ES, Reynolds SA, Levy F, Sarubbi FA. An outbreak of infections caused by non-typeable Haemophilus influenzae in an extended care facility. J Hosp Infect. 2007; 66(1):59–64
10.1016/j.jhin.2007.02.001 Crossref Medline, Google Scholar - 25.Buck JM, Lexau C, Shapiro M, A community outbreak of conjunctivitis caused by nontypeable Streptococcus pneumoniae in Minnesota. Pediatr Infect Dis J. 2006; 25(10):906–911.
10.1097/01.inf.0000238143.96607.ec Crossref Medline, Google Scholar - 26.Ohnsman CM. Exclusion of students with conjunctivitis from school: policies of state departments of health. J Pediatr Ophthalmol Strabismus. 2007; 44(2):101–105. Link, Google Scholar
- 27.Cavuoto K, Zutshi D, Karp CL, Miller D, Feuer W. Update on bacterial conjunctivitis in South Florida. Ophthalmology. 2008; 115(1):51–56.
10.1016/j.ophtha.2007.03.076 Crossref Medline, Google Scholar - 28.Mah F. The benefits of fourth-generation fluoroquinolones in the prevention of ocular bacterial infections. Clin Surg Ophthalmol. 2004; 22(8):228–231. Google Scholar
- 29.DailyMed. dailymed.nlm.nih.gov/dailymed/. Accessed June 7, 2010. Google Scholar
- 30.Drug Facts and Comparisons. St. Louis, MO: Wolters Kluwer; 2008:1764–1765. Google Scholar
- 31.Gwon A. Ofloxacin vs tobramycin for the treatment of external ocular infection. Ofloxacin Study Group II. Arch Ophthalmol. 1992; 110(9):1234–1237. Crossref Medline, Google Scholar
- 32.Cagle G, Davis S, Rosenthal A, Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res. 1981–1982(9):523–534.
10.3109/02713688109069178 Crossref Medline, Google Scholar - 33.Leibowitz HM, Hyndiuk RA, Smolin GR, Tobramycin in external eye disease: a double-masked study vs. gentamicin. Curr Eye Res. 1981; 1(5):259–266.
10.3109/02713688108999445 Crossref Medline, Google Scholar - 34.Timewell RM, Rosenthal AL, Smith JP, Cagle GD. Safety and efficacy of tobramycin and gentamicin sulfate in the treatment of external ocular infections of children. J Pediatr Ophthalmol Strabismus. 1983; 20(1):22–26. Link, Google Scholar
- 35.Genée E, Schlechtweg C, Bauerreiss P, Gibson JR. Trimethoprim-polymyxin eye drops versus neomycin-polymyxin-gramicidin eye drops in the treatment of presumptive bacterial conjunctivitis - a double-blind study. Ophthalmologica. 1982; 184(2):92–96.
10.1159/000309190 Crossref Medline, Google Scholar - 36.Lamberts DW, Buka T, Knowlton GM. Clinical evaluation of trimethoprim-containing ophthalmic solutions in humans. Am J Ophthalmol. 1984; 98(1):11–16.
10.1016/0002-9394(84)90181-8 Crossref Medline, Google Scholar - 37.Gigliotti F, Hendley JO, Morgan J, Michaels R, Dickens M, Lohr J. Efficacy of topical antibiotic therapy in acute conjunctivitis in children. J Pediatr. 1984; 104(4):623–626.
10.1016/S0022-3476(84)80566-1 Crossref Medline, Google Scholar - 38.Lohr JA, Austin RD, Grossman M, Hayden GF, Knowlton GM, Dudley SM. Comparison of three topical antimicrobials for acute bacterial conjunctivitis. Pediatr Infect Dis J. 1988; 7(9):626–629.
10.1097/00006454-198809000-00005 Crossref Medline, Google Scholar - 39.Wald ER, Greenberg D, Hoberman A. Short term oral cefixime therapy for treatment of bacterial conjunctivitis. Pediatr Infect Dis J. 2001; 20(11):1039–1042.
10.1097/00006454-200111000-00007 Crossref Medline, Google Scholar - 40.Abelson MB, Heller W, Shapiro AM, Si E, Hsu P, Bowman LMAzaSite Clinical Study Group. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial. Am J Ophthalmol. 2008; 145(6):959–965.
10.1016/j.ajo.2008.01.019 Crossref Medline, Google Scholar - 41.Protzko E, Bowman L, Abelson M, Shapiro AAzaSite Clinical Study Group. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007; 48(8):3425–3429.
10.1167/iovs.06-1413 Crossref Medline, Google Scholar - 42.Kaliamurthy J, Nelson Jesudasan CA, Geraldine P, Parmar P, Kalavathy CM, Thomas PA. Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic Res. 2005; 37(3):117–122.
10.1159/000084270 Crossref Medline, Google Scholar - 43.Hwang DG. Fluoroquinolone resistasnce in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004; 49(Suppl 2):S79–S83.
10.1016/j.survophthal.2004.01.004 Crossref Medline, Google Scholar - 44.Chen FJ, Lo HJ. Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect. 2003; 36(1):1–9. Crossref Medline, Google Scholar
- 45.Morrissey I, Hoshino K, Sato K, Mechanism of differential activities of ofloxacin enantiomers. Antimicrob Agents Chemother. 1996; 40(8):1775–1784. Crossref Medline, Google Scholar
- 46.Scoper SV. Review of third- and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy. Adv Ther. 2008; 25(10):979–994.
10.1007/s12325-008-0107-x Crossref Medline, Google Scholar - 47.US Food and Drug Administration. Drugs @ FDA. FDA-approved drug products. Available at: www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed Sept. 14, 2010. Google Scholar
- 48.Besivance [package insert]. Rochester, NY: Bausch & Lomb Inc; 2009. Google Scholar
- 49.Nafziger AN, Bertino JS. Besifloxacin ophthalmic suspension for bacterial conjunctivitis. Drugs Today (Barc). 2009; 45(8):577–588.
10.1358/dot.2009.45.8.1417975 Crossref Medline, Google Scholar - 50.Tepedino ME, Heller WH, Usner DW, Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009; 25(5):1159–1169.
10.1185/03007990902837919 Crossref Medline, Google Scholar - 51.Karpecki P, Depaolis M, Hunter JA, Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009; 31(3):514–526.
10.1016/j.clinthera.2009.03.010 Crossref Medline, Google Scholar - 52.McDonald MB, Protzko EE, Brunner , Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 2009; 116(19):1615–1623.
10.1016/j.ophtha.2009.05.014 Crossref Medline, Google Scholar - 53.Silverstein B, Allaire C, Bateman KM, Gearinger LS, Morris TW, Comstock TL. Efficacy and safety of besifloxacin 0.6% ophthalmic suspension administered twice a day for three days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, phase II study. Clin Ther. In press. Google Scholar
- 54.Lichtenstein SJ, Wagner RS, Jamison T, Bell B, Stroman DW. Speed of bacterial kill with a fluoroquinolone compared with non-fluoroquinolones: clinical implications and a review of kinetics of kill studies. Adv Ther. 2007; 24(5):1098–1111.
10.1007/BF02877716 Crossref Medline, Google Scholar - 55.Wagner RS, Granet DB, Lichtenstein SJ, Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin, a fluoroquinolone, compared with the aminoglycosides tobramycin and gentamicin. Clin Ophthalmol. 2010; 4:41–45. Medline, Google Scholar
- 56.Gross RD, Hoffman RO, Lindsay RN. A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. Clin Pediatr (Phila). 1997; 36(6):435–444.
10.1177/000992289703600801 Crossref Medline, Google Scholar - 57.Granet DB, Dorfman M, Stroman D, Cockrum P. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2008; 45(6):340–349.
10.3928/01913913-20081101-07 Link, Google Scholar - 58.Lichtenstein SJ, Rinehart MLevofloxacin Bacterial Conjunctivitis Study Group. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS. 2003; 7(5):317–324.
10.1016/S1091-8531(03)00168-X Crossref Medline, Google Scholar - 59.Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CTLevofloxacin Bacterial Conjunctivitis Active Control Study Group. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology. 2003; 110(3):457–465.
10.1016/S0161-6420(02)01894-8 Crossref Medline, Google Scholar - 60.Hwang DG, Schanzlin DJ, Rotberg MH, Foulks G, Raizman MBLevofloxacin Bacterial Conjunctivitis Place-controlled Study Group. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol. 2003; 87(8):1004–1009.
10.1136/bjo.87.8.1004 Crossref Medline, Google Scholar - 61.Stratton CW. Dead bugs don’t mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis. 2003; 9(1):10–16. Crossref Medline, Google Scholar
- 62.McDonald M, Blondeau JM. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones. J Cataract Refract Surg. 2010; 36(9):1588–1598.
10.1016/j.jcrs.2010.06.028 Crossref Medline, Google Scholar - 63.Asbell PA, Sahm DF, Shaw M, Draghi DC, Brown NP. Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005. J Cataract Refract Surg. 2008; 34(5):814–818.
10.1016/j.jcrs.2008.01.016 Crossref Medline, Google Scholar - 64.Asbell PA, Colby KA, Deng S, Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol. 2008; 145(6):951–958.
10.1016/j.ajo.2008.01.025 Crossref Medline, Google Scholar - 65.Morrissey I, Burnett R, Viljoen L, Robbins M. Surveillance of the susceptibility of ocular bacterial pathogens to the fluoroquinolone gatifloxacin and other antimicrobials in Europe during 2001/2002. J Infect. 2004; 49(2):109–114.
10.1016/j.jinf.2004.03.007 Crossref Medline, Google Scholar - 66.Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000; 107(8):1497–1502.
10.1016/S0161-6420(00)00179-2 Crossref Medline, Google Scholar - 67.Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis. 2009; 15(8):1260–1264.
10.3201/eid1508.081187 Crossref Medline, Google Scholar - 68.Ohnsman C, Ritterband D, O’Brien T, Girgis D, Kabat A. Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. Curr Med Res Opin. 2007; 23(9):2241–2249.
10.1185/030079907X226276 Crossref Medline, Google Scholar - 69.Blondeau JM. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemother. 2004; 16(Suppl 3):1–19. Crossref Medline, Google Scholar
- 70.Chalita MR, Höfling-Lima AL, Paranhos A, Schor P, Belfort R. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol. 2004; 137(1):43–51.
10.1016/S0002-9394(03)00905-X Crossref Medline, Google Scholar - 71.Haas W, Pillar C, Torres M, Morris TW, Sahm D. ARMOR, a new prospective, multicenter surveillance study to determine the in vitro activity profile of besifloxacin and comparators against ocular pathogens from the US.
Poster presented at: 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology ;May 2–6, 2010 ;Fort Lauderdale, FL . Google Scholar - 72.Lu T, Zhao X, Li X, Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother. 2001; 45(10):2703–2709.
10.1128/AAC.45.10.2703-2709.2001 Crossref Medline, Google Scholar - 73.Ward KW, Lepage JF, Driot JY. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmacol Ther. 2007; 23(3):243–256.
10.1089/jop.2006.0137 Crossref Medline, Google Scholar
